Tadocizumab

Tadocizumab
Monoclonal antibody
Type	Fab fragment
Source	Humanized (from mouse)
Target	Integrin αIIbβ3
Clinical data
ATC code	none;
Identifiers
CAS Number	339086-80-5 ;
ChemSpider	none;
UNII	R34T642CGV;
Chemical and physical data
Formula	C2107H3252N562O673S12
Molar mass	47609.17 g·mol−1
	(verify)

Tadocizumab is a humanized monoclonal antibody that acts on the cardiovascular system.^[1] It binds to integrin α_IIbβ₃, a fibrinogen and fibronectin receptor found on platelets.^[2]

The drug is designed for the treatment of patients undergoing percutaneous coronary interventions. It was developed by Yamanōchi Pharma America, Inc.^[1]

References

^ ^a ^b Statement On A Nonproprietary Name Adopted By The USAN Council - Tadocizumab, American Medical Association.
^ Molecular cell biology. Lodish, Harvey F. 5. ed. : – New York : W. H. Freeman and Co., 2003, 973 s. b ill. ISBN 0-7167-4366-3

[USAN-1] Statement On A Nonproprietary Name Adopted By The USAN Council - Tadocizumab, American Medical Association.

[lodish-2] Molecular cell biology. Lodish, Harvey F. 5. ed. : – New York : W. H. Freeman and Co., 2003, 973 s. b ill. ISBN 0-7167-4366-3

[1]

[2]